Press Releases for PPCO

Press Releases
Penwest Reports Second Quarter 2009 Financial Results
Penwest Second Quarter 2009 Financial Results Conference Call
Penwest Announces Results of Phase Ib Trial of A0001
Penwest Announces That the Results of Its Annual Meeting Have Been Certified
Penwest Enters Into Third Research and Development Agreement With Otsuka Pharmaceutical
Shareholders Elect Tang Capital and Perceptive Nominees and Approve Shareholder Resolution
Penwest Announces Preliminary Vote Count At Annual Meeting
Penwest Urges Shareholders to Vote the White Proxy Card Today and Reject Dissident Proposals and Nominees At Wednesday's Annual Meeting
Penwest and Endo Grant Valeant Pharmaceuticals Exclusive License to Market Opana(R) ER in Canada, Australia and New Zealand; Agreement Demonstrates Value of OPANA ER in Markets Outside U.S.
Penwest and Endo Grant Valeant Pharmaceuticals Exclusive License to Market Opana(r) ER in Canada, Australia and New Zealand
Tang Capital and Perceptive Urge All Penwest Shareholders to Vote Today and Vote for Change at Penwest Pharmaceuticals Co.
Three Proxy Advisory Firms Unanimously Support Tang Capital and Perceptive’s Director Nominees for Penwest Pharmaceuticals Co.
Leading Proxy Advisory Firms RiskMetrics Group and Glass Lewis Recommend Penwest Shareholders Vote Against All Three Dissident Proxy Proposals
Tang Capital Partners, LP and Perceptive Life Sciences Master Fund Ltd. Announce Plan to Seek Expedited Trial in Case Against Penwest Pharmaceuticals Co.
Washington State Court Denies Dissidents' Request for Preliminary Injunction in Penwest Proxy Vote
Penwest Urges Shareholders to Reject Tang Capital and Perceptive's Wind Down Proposal
Tang Capital Partners, LP and Perceptive Life Sciences Master Fund Ltd. Urge the Shareholders of Penwest Pharmaceuticals Co. To Vote for Their Shareholder Proposals
Penwest Files Definitive Proxy Materials in Connection With June 10 Annual Meeting
Penwest Reports First Quarter 2009 Financial Results
Penwest First Quarter 2009 Financial Results Conference Call
Tang Capital Partners, LP and Perceptive Life Sciences Master Fund Ltd. Comment on Penwest Proxy Filing
Penwest Sends Letter to Shareholders On Financial, Business and Corporate Governance Developments
Penwest to Present At Cowen & Company 29th Annual Healthcare Conference
Penwest Reports Fourth Quarter and Year End 2008 Financial Results
Tang Capital Partners, LP and Perceptive Life Sciences Master Fund Ltd. Urge the Board of Directors of Penwest Pharmaceuticals Co. to Take Immediate Action to Preserve Shareholder Value
Penwest Begins Phase Ib Clinical Trial of A0001, Dosing Underway of Compound for the Treatment of Mitochondrial Diseases
Penwest Fourth Quarter and Year End 2008 Financial Results Conference Call
Endo and Penwest Announce Settlement of Opana(R) ER Litigation
Penwest to Present At 11th Annual BIO CEO & Investor Conference
Penwest Sets Focused Priorities for 2009; Takes Actions to Further Reduce Costs
Penwest to Present At RBC Capital Markets Healthcare Conference
Penwest Enters Into Second Research and Development Agreement With Otsuka Pharmaceutical
Penwest Reports Third Quarter 2008 Financial Results
Penwest Third Quarter 2008 Financial Results Conference Call
Penwest Reports Second Quarter 2008 Financial Results
BeaconEquity.com Issues Trade Alerts on Market Movers: WEL, LGND, PPCO, KIDS, GNLK, VCSY
Penwest Second Quarter 2008 Financial Results Conference Call
Penwest to Present At Two Upcoming Conferences
Penwest Begins Phase Ia Clinical Trial of A0001, a Compound For Treatment of Mitochondrial Diseases
Penwest Begins Phase I Clinical Trial of PW 4153, Candidate For Treatment of Symptoms of Parkinson's Disease
Penwest Enters Into Development and Licensing Agreement With Cobalt Laboratories - May 27 2008 12:57AM
Penwest to Present At Upcoming Conferences
Penwest 2007 Annual Report to Shareholders Now Available Online
Penwest Reports First Quarter 2008 Financial Results
Penwest First Quarter 2008 Financial Results Conference Call